Allogeneic hematopoietic stem cell transplantation at the Clinical Center of Vojvodina

. Allogenic hematopoietic stem cell transplantation is the best therapeutic option for the treatment of some inherited and acquired diseases of the hematopoietic system as well as various hematological malignancies. Material and Methods. The study was conducted as a retrospective analysis of 35 patients who underwent allogenic hematopoietic stem cell transplantation at the Clinic of Hematology, Clinical Center of Vojvodina. Results. In a group of 35 patients with median age 33 years, 13 patients had acute myeloid leukemia, one patient had acute lymphoblastic leukemia, nine had chronic myeloid leukemia, five had aplastic anemia, five myelodysplastic syndrome, one had multiple myeloma and one had Ewing sarcoma. Nine patients (26%) had an advanced, resistant disease at the time of transplantation. The majority of patients had a matched related transplantation - 89% (31/35) - three patients had syngeneic transplantation, and one patient had a haploidentical transplantation. Out of 35 patients, 16 (45.7%) are alive. The European Bone Marrow Transplantation score ?3 and the presence of advanced disease at the time of transplant were unfavourable prognostic factors for survival (p<0.01). If we exclude the cases with advanced, resistant disease at the time of transplantation, the probability of 5-year survival rate was as follows: 100% in patients with aplastic anemia, 75% in patients with acute leukemia, 34% in myelodysplastic syndrome, and 14% in chronic myeloid leukemia patients. Conclusion. The outcome of allogeneic hematopoietic stem cells transplantation in our patients is generally comparable with previously reported results. The main prognostic factors for survival were European Bone Marrow Transplantation risk score and disease status at the time of transplantation.